Navigation Links
Common Antidepressants Linked to Increased Bone Loss in Older Adults

Two studies have found that a class of commonly prescribed antidepressants may be linked to an increased rate of bone loss in older men and women .

The antidepressant medications known as selective serotonin reuptake inhibitors (SSRIs) treat depression by inhibiting the protein that transports serotonin, a neurotransmitter involved in sleep and depression, according to background information in the articles, and which has recently been discovered in bone as well.

The findings raise the possibility that SSRIs, which are often prescribed to the elderly, may affect bone density and the risk of fracture.

The first study was conducted by a team of researchers from the University of Minnesota led by Dr Susan J Diem.

The researches studied 2,722 older women, with an average age 78.5 years, beginning in 1997 through 1999. At that time and again an average of 4.9 years later, researchers measured women's total hip bone density and also that of two subregions.

At each visit, the participants were asked to bring in all the medications they had used within the past two weeks, including SSRIs and tricyclic antidepressants, which work through a different mechanism.

A total of 198 (7.3 percent) of the women were SSRI users, 118 (4.3 percent) took tricyclic antidepressants and 2,406 (88.4 percent) took neither (those who took both were not included in the analysis).

After adjusting for other factors affecting bone density and antidepressant use, including depression severity and calcium supplement use, bone mineral density at the hip decreased 0.82 percent in SSRI users.

This compared with a decrease of 0.47 percent among those who used tricyclic antidepressants and also in those who did not take any antidepressants. Higher rates of bone loss were also observed at the two hip subregions among SSRI users.

"One potential explanation for our findings is that SS RI use may have a direct deleterious effect on bone. This theory is supported by findings of in vitro and in vivo laboratory investigations," they write.

"Our findings suggest that, in this cohort, use of SSRIs is associated with increased rates of hip bone loss. Further investigation of SSRI use and rates of change in bone mineral density in other populations with longer follow-up is warranted given the recent description of serotonin transporters in bone," the authors conclude.

The second study, 5,995 men age 65 and older (average age 73.7), was conducted by researchers led by Dr Elizabeth M. Haney, of Oregon Health and Sciences University, Portland.

The men's bone density at the hip, including subregions, and at the base of the spine were measured between 2000 and 2002. Participants were asked to bring all medications to their clinic visit, where they were also given a physical examination and asked about other health and lifestyle factors.

A total of 160 (2.7 percent) men reported using SSRIs, 99 (1.7 percent) reported using tricyclic antidepressants and 52 (0.9 percent) reported using trazodone, a third type of antidepressant. Total hip bone mineral density was 3.9 percent lower among SSRI users than among men who didn't use any antidepressants. Similarly, spine bone mineral density was 5.9 percent lower among SSRI users than among non-users.

There was no significant difference in either hip or spine density between men who took tricyclic antidepressants or trazodone and those who did not take antidepressants.

"These associations are biologically plausible and clinically important. Because SSRI use is prevalent in the general population, our findings have a potentially important public health impact. If confirmed, people using SSRIs might be targeted for osteoporosis screening and preventive intervention," the authors write.

The two studies appear in the June 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.


'"/>




Related medicine news :

1. Common contraception
2. Common Cold Remedy May Treat SARS
3. Common Plant Triggers Asthma
4. Pain Common in People with MS
5. Common Cold Found to Fight Cancer
6. Bullying – a Common Problem Among Childre
7. Common Medication Errors in Children
8. A Common Cause Of Allergy That Goes Unnoticed
9. Genetic Breakthrough in Common Eye Problem
10. Common Cold Found to Fight Cancer Cells
11. Side Effects Of Some Common Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
Breaking Medicine Technology: